Entera Bio Ltd. Logo

Entera Bio Ltd.

Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.

ENTX | US

Overview

Corporate Details

ISIN(s):
IL0011429839
LEI:
Country:
United States of America
Address:
KIRYAT HADASSAH, MINRAV BUILDING, 9112002 JERUSALEM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of orally delivered large molecule and peptide therapeutics. The company's proprietary N-Tab™ technology platform enables the oral administration of drugs that are typically injectable by stabilizing the active ingredients in the gastrointestinal tract and enhancing absorption. Entera's primary focus is on therapies for significant unmet medical needs. Its clinical pipeline is led by EB613, an oral parathyroid hormone (PTH) tablet for postmenopausal women with osteoporosis, and EB612 for patients with hypoparathyroidism. The company is also developing oral treatments for obesity and rare malabsorption conditions like short bowel syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Entera Bio Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Entera Bio Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Entera Bio Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea
308080
Viking Therapeutics, Inc. Logo
Biopharma developing novel therapies for metabolic and endocrine disorders like obesity and NASH.
United States of America
VKTX
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France
FR000
Vir Biotechnology, Inc. Logo
Immunology company developing antibody therapies for serious infectious diseases and cancer.
United States of America
VIR
Viridian Therapeutics, Inc.\DE Logo
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
United States of America
VRDN
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark
VIRO
Vistagen Therapeutics, Inc. Logo
Biopharma firm developing intranasal therapies for anxiety, depression & neurological disorders.
United States of America
VTGN
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway
VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany
V3V
Vivani Medical, Inc. Logo
Develops long-term subdermal drug implants for chronic diseases like diabetes & weight management.
United States of America
VANI

Talk to a Data Expert

Have a question? We'll get back to you promptly.